According to the latest report by IMARC Group, titled “Cervical Cancer Diagnostics Market Report by Test Type (Pap Testing, HPV Testing, Cervical Biopsies, Colposcopy, and Others), Age Group (20 to 35 Years, Above 35 Years), and Region 2025-2033,” the global cervical cancer diagnostics market reached a value of USD 8.3 Billion in 2024. Cervical cancer refers to a type of cancer that occurs in the cervix, the lower part of the uterus. There are two main types of cervical cancer, namely adenocarcinoma and squamous cell carcinoma. Cervical cancer diagnosis is performed through various advanced laboratory tests, tools and procedures to evaluate abnormal cells and strains of human papillomavirus (HPV). These tests and procedures include conization, punch biopsy, endocervical curettage and the electrical wire loop for a thorough examination of the cervix during colposcopy. These procedures are followed by blood tests, body computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) scans to determine the progress of the disease.
Global Cervical Cancer Diagnostics Market Trends:
The rising prevalence of sexually transmitted infections (STIs) is one of the key factors driving the global cervical cancer diagnostics market growth. Other than this, the growing adoption of advanced diagnostic procedures for the early detection of cervical cancer, along with various awareness campaigns organized by government and non-government entities, is also contributing to the market growth. In line with this, there is a growing consciousness regarding the availability of effective treatment and diagnosis methods, which is further contributing to the market growth. Leading players are developing home-based HPV testing kits to offer convenience to consumers, which is acting as another major growth-inducing factor. Additionally, the escalating demand for minimally invasive screening procedures is supporting the market growth. Moreover, the growing emphasis on developing low-cost and efficient testing products is creating a positive outlook for the market. Looking forward, the market value is projected to reach USD 12.7 Billion by 2033, expanding at a CAGR of 4.56% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Test Type, Age Group, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, Arbor Vita Corporation, Becton, Dickinson and Company, Cooper Surgical Inc., F. Hoffmann-La Roche AG, Guided Therapeutics Inc., Hologic Inc., Qiagen, Quest Diagnostics Incorporated and Siemens Healthcare GmbH |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal